ebyxcy9

Property	Value
?:abstract	OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS) METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020 We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included Among them, 111 (0 33%) patients with aNMD and 115 patients (0 27%) with MS had COVID-19 About one third of them required hospitalization IST did not appear to have a significant impact on overall infection risk in either group;however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2 86, p-value 0 011) CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19 IST may be continued during the pandemic, as previously suggested by expert opinion guidelines However, it is important to consider individualizing immunotherapy regimens in some cases Additional physician reported registry-based data is needed to further confirm these findings OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS. RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011). CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/2ebyxcy9_hasAnnotation_C1373218> <https://research.tib.eu/covid-19/entity/2ebyxcy9_hasAnnotation_C1825598>
?:creator	<https://research.tib.eu/covid-19/entity/Kovvuru%2C_S.%3B_Nalleballe%2C_K.%3B_Onteddu%2C_S._R.%3B_Sharma%2C_R.%3B_Jasti%2C_M.%3B_Kapoor%2C_N.%3B_Veerapaneni%2C_K.%3B_Yadala%2C_S.%3B_Dandu%2C_V.%3B_Archer%2C_R.%3B_Nowak%2C_R._J.%3B_Roy%2C_B.> <https://research.tib.eu/covid-19/entity/Kovvuru%2C_Sukanthi%3B_Nalleballe%2C_Krishna%3B_Onteddu%2C_Sanjeeva_Reddy%3B_Sharma%2C_Rohan%3B_Jasti%2C_Madhu%3B_Kapoor%2C_Nidhi%3B_Veerapaneni%2C_Karthika%3B_Yadala%2C_Sisira%3B_Dandu%2C_Vasuki%3B_Archer%2C_Robert%3B_Nowak%2C_Richard_J%3B_Roy%2C_Bhaskar>
?:journal	J_Neurol_Sci Journal_of_the_Neurological_Sciences
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/2ebyxcy9_HAS_C1373218_COEXISTS_WITH_C1290882>
?:source	WHO
?:title	Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1065368 #951880
?:year	2020 2021

Property

Value

?:abstract

OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS) METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020 We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included Among them, 111 (0 33%) patients with aNMD and 115 patients (0 27%) with MS had COVID-19 About one third of them required hospitalization IST did not appear to have a significant impact on overall infection risk in either group;however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2 86, p-value 0 011) CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19 IST may be continued during the pandemic, as previously suggested by expert opinion guidelines However, it is important to consider individualizing immunotherapy regimens in some cases Additional physician reported registry-based data is needed to further confirm these findings
OBJECTIVE: To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). METHODS: We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders (aNMD) [myasthenia gravis (MG), inflammatory myositis, and chronic inflammatory neuropathies (CIN)] and MS, based on the International Classification of Disease-10 (ICD-10) coding for one year before January 20th, 2020. We examined the use of IST, rate of COVID- 19, hospitalization, intubation, and mortality among the patients with aNMD and MS. RESULTS: A total of 33,451 patients with aNMD and 42,899 patients with MS were included. Among them, 111 (0.33%) patients with aNMD and 115 patients (0.27%) with MS had COVID-19. About one third of them required hospitalization. IST did not appear to have a significant impact on overall infection risk in either group; however, risk of hospitalization for immunosuppressed patients with aNMD was higher (Odds ratio 2.86, p-value 0.011). CONCLUSIONS: IST use does not appear to make patients with aNMD and MS more vulnerable to COVID-19. IST may be continued during the pandemic, as previously suggested by expert opinion guidelines. However, it is important to consider individualizing immunotherapy regimens in some cases. Additional physician reported registry-based data is needed to further confirm these findings.

is ?:annotates of